Citations (155)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (29)
Florian Simon, Adam Giza, Sandra Robrecht, Anna-Maria Fink, Paula Cramer, Julia von Tresckow, Moritz Fürstenau, Valentin Goede, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Clemens-Martin Wendtner, Barbara Eichhorst, Kirsten Fischer, Michael Hallek & Othman Al-Sawaf. (2022) Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older. Leukemia & Lymphoma 63:14, pages 3299-3306.
Read now
Read now
Emelie C Rotbain, Klaus Rostgaard, Michael A Andersen, Caspar Da Cunha-Bang, Carsten U Niemann, Henrik Frederiksen & Henrik Hjalgrim. (2021) Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia. Clinical Epidemiology 13, pages 1155-1165.
Read now
Read now
Hee Jeong Cho, Dong Won Baek, Juhyung Kim, Jung Min Lee, Joon Ho Moon & Sang Kyun Sohn. (2021) Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Expert Review of Hematology 14:9, pages 819-830.
Read now
Read now
Jacqueline C. Barrientos, Peter Hillmen, Gilles Salles, Jeff Sharman, Stephan Stilgenbauer, Oksana Gurtovaya, Guan Xing, Bianca Ruzicka, Pankaj Bhargava, Paolo Ghia & John M. Pagel. (2021) No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Leukemia & Lymphoma 62:4, pages 837-845.
Read now
Read now
Stefano Molica. (2020) The evolving role of time-limited targeted therapy in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 20:12, pages 1015-1019.
Read now
Read now
Stefano Molica, Diana Giannarelli, Luciano Levato, Rosanna Mirabelli, Domenico Levato, Mirella Lentini & Eugenio Piro. (2019) A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients. Leukemia & Lymphoma 60:3, pages 845-847.
Read now
Read now
Lauren J. Lee, Cynthia L. Toze, Steven J. T. Huang, Tanya L. Gillan, Joseph M. Connors, Laurie H. Sehn, Helene Bruyere, Heather Leitch, Khaled M. Ramadan & Alina S. Gerrie. (2018) Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada. Leukemia & Lymphoma 59:6, pages 1356-1363.
Read now
Read now
Moushmi Singh, Stuart Mealing, Simona Baculea, Sarah Cote & Jo Whelan. (2017) Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy. Journal of Medical Economics 20:10, pages 1066-1073.
Read now
Read now
Max J. Gordon, Lionel D. Lewis, Jennifer R. Brown & Alexey V. Danilov. (2017) Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities – is there an optimal dose?. Expert Review of Hematology 10:8, pages 707-718.
Read now
Read now
Tait D. Shanafelt, Sameer A. Parikh, Peter A. Noseworthy, Valentin Goede, Kari G. Chaffee, Jasmin Bahlo, Timothy G. Call, Susan M. Schwager, Wei Ding, Barbara Eichhorst, Kirsten Fischer, Jose F. Leis, Asher Alban Chanan-Khan, Michael Hallek, Susan L. Slager & Neil E. Kay. (2017) Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leukemia & Lymphoma 58:7, pages 1630-1639.
Read now
Read now
Peter Martin, Paul M. Barr, Leonard James, Ashutosh Pathak & Brad Kahl. (2017) Long-term safety experience with bendamustine for injection in a real-world setting. Expert Opinion on Drug Safety 16:6, pages 647-650.
Read now
Read now
Candida Vitale, Valentina Griggio, Maria Todaro, Chiara Salvetti, Mario Boccadoro & Marta Coscia. (2017) Magic pills: new oral drugs to treat chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 18:4, pages 411-425.
Read now
Read now
Francesca R. Mauro, Adriano Salaroli, Maria D. Caputo, Gioia Colafigli, Luigi Petrucci, Melissa Campanelli, Antonietta Ferretti, Anna R Guarini & Robin Foà. (2016) Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Review of Hematology 9:12, pages 1165-1175.
Read now
Read now
Lev Shvidel & Alain Berrebi. (2016) Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?. Expert Review of Hematology 9:3, pages 245-254.
Read now
Read now
Valentin Goede, Barbara Eichhorst, Kirsten Fischer, Clemens-Martin Wendtner & Michael Hallek. (2015) Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia. Leukemia & Lymphoma 56:6, pages 1585-1592.
Read now
Read now
Stefano Molica. (2015) Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial. Expert Review of Anticancer Therapy 15:1, pages 9-15.
Read now
Read now
Zahra Mozaheb. (2014) Treating the elderly patient with chronic lymphocytic leukemia: current and emerging options. Blood and Lymphatic Cancer: Targets and Therapy 4, pages 9-14.
Read now
Read now
Stefano Molica, Maura Brugiatelli, Fortunato Morabito, Felicetto Ferrara, Emilio Iannitto, Nicola Di Renzo, Silvana Capalbo, Pellegrino Musto & Francesco Di Raimondo. (2013) Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need. Expert Review of Hematology 6:4, pages 441-449.
Read now
Read now
Clive S. Zent. (2012) Improving quality of life in chronic lymphocytic leukemia. Leukemia & Lymphoma 53:7, pages 1247-1248.
Read now
Read now
Ali Bazargan, Constantine S Tam & Michael J Keating. (2012) Predicting survival in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 12:3, pages 393-403.
Read now
Read now
Ilaria Del Giudice, Francesca Romana Mauro & Robin Foà. (2011) Chronic lymphocytic leukemia in less fit patients: “slow-go”. Leukemia & Lymphoma 52:12, pages 2207-2216.
Read now
Read now
Peter H. Wiernik & Giridhar U. Adiga. (2011) Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. Current Medical Research and Opinion 27:10, pages 1987-1993.
Read now
Read now
Clive S. Zent & Neil E. Kay. (2011) Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leukemia & Lymphoma 52:8, pages 1425-1434.
Read now
Read now
Leslie A Andritsos & Michael R Grever. (2011) Salvage therapy for relapsed chronic lymphocytic leukemia. Expert Review of Hematology 4:2, pages 199-212.
Read now
Read now
Pau Abrisqueta, Marta Crespo & Francesc Bosch. (2011) Personalizing treatment for chronic lymphocytic leukemia. Expert Review of Hematology 4:1, pages 27-35.
Read now
Read now
Ali Bazargan & Constantine S. Tam. (2010) New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents. Leukemia & Lymphoma 51:9, pages 1596-1611.
Read now
Read now
John G Gribben. (2010) Chronic lymphocytic leukemia: planning for an aging population. Expert Review of Anticancer Therapy 10:9, pages 1389-1394.
Read now
Read now
Tait D. Shanafelt, Kari G. Rabe, Neil E. Kay, Clive S. Zent, Timothy G. Call, Susan L. Slager, Deborah A. Bowen, Susan M. Schwager & Grzegorz S. Nowakowski. (2010) Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leukemia & Lymphoma 51:7, pages 1233-1240.
Read now
Read now
Barbara Eichhorst, Valentin Goede & Michael Hallek. (2009) Treatment of elderly patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 50:2, pages 171-178.
Read now
Read now
Articles from other publishers (126)
Candida Vitale, Valentina Griggio, Francesca Perutelli & Marta Coscia. (2023) CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?. HemaSphere 7:12, pages e988.
Crossref
Crossref
Lukáš Smolej. (2023) Modern approach to the treatment of chronic lymphocytic leukemia. Onkologie 17:4, pages 273-281.
Crossref
Crossref
Max J. Gordon, Jade E. Jones, Binsah George, Christine Peterson, Jan A. Burger, Nitin Jain, Michael Keating, William G. Wierda, Jean‐Bernard Durand & Alessandra Ferrajoli. (2023) Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer 129:14, pages 2192-2200.
Crossref
Crossref
Jiayu Yang, Lin Yang, Bryan Tordon, Oliver Bucher, Zoann Nugent, Ivan Landego, Nicole Bourrier, Kelsey Uminski, Kevin Brown, Mandy Squires, Aaron J. Marshall, Sachin Katyal, Salah Mahmud, Kathleen Decker, Marc Geirnaert, David E. Dawe, Spencer B. Gibson, James B. Johnston & Versha Banerji. (2023) Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade. Current Oncology 30:7, pages 6411-6431.
Crossref
Crossref
Max J. Gordon, Zhigang Duan, Hui Zhao, Loretta Nastoupil, Alessandra Ferrajoli, Alexey V. Danilov & Sharon H. Giordano. (2023) A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. Blood Advances 7:11, pages 2632-2642.
Crossref
Crossref
Justin C. Crane, Max J. Gordon, Karen Basen‐Engquist, Alessandra Ferrajoli, Melissa M. Markofski, Che Young Lee, Sara Fares, Richard J. Simpson & Emily C. LaVoy. (2023) Relationships between T‐lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study. European Journal of Haematology 110:6, pages 732-742.
Crossref
Crossref
Emelie Curovic Rotbain, Cristine Allmer, Klaus Rostgaard, Michael Asger Andersen, Noomi Vainer, Caspar da Cunha‐Bang, Sameer A. Parikh, Kari G. Rabe, Henrik Hjalgrim, Henrik Frederiksen, Susan L. Slager & Carsten Utoft Niemann. (2023) Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia. American Journal of Hematology.
Crossref
Crossref
Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Sumeet Panjabi, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang & Michael Choi. (2022) Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. Clinical Lymphoma Myeloma and Leukemia 22:11, pages e959-e971.
Crossref
Crossref
Darcy B. Pooler, Dylan B. Ness, Alexey V. Danilov, Bridget M. Labrie, Tor D. Tosteson, Alan Eastman, Lionel D. Lewis & Frederick Lansigan. (2022) A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. eJHaem 3:4, pages 1445-1448.
Crossref
Crossref
Renata Walewska, Nilima Parry‐Jones, Toby A. Eyre, George Follows, Nicolas Martinez‐Calle, Helen McCarthy, Helen Parry, Piers E. M. Patten, John C. Riches, Peter Hillmen & Anna H. Schuh. (2022) Guideline for the treatment of chronic lymphocytic leukaemia. British Journal of Haematology 197:5, pages 544-557.
Crossref
Crossref
Anna Maria Frustaci, Marina Deodato, Giulia Zamprogna, Roberto Cairoli, Marco Montillo & Alessandra Tedeschi. (2022) SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?. Clinical Lymphoma Myeloma and Leukemia 22:6, pages 356-361.
Crossref
Crossref
Emelie C. Rotbain, Max J. GordonNoomi VainerHenrik Frederiksen, Henrik Hjalgrim, Alexey V. Danilov & Carsten U. Niemann. (2022) The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. Blood Advances 6:8, pages 2701-2706.
Crossref
Crossref
Maura Dowling & Mary B Kelly. (2022) Acalabrutinib in the management of chronic lymphocytic leukaemia. Journal of Prescribing Practice 4:2, pages 72-80.
Crossref
Crossref
Vilhjálmur Steingrímsson, Sigrún H. Lund, Paul W. Dickman, Caroline E. Weibull, Magnus Björkholm, Ola Landgren & Sigurður Y. Kristinsson. (2021) Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre‐ibrutinib era: A population‐based study. European Journal of Haematology 108:2, pages 145-153.
Crossref
Crossref
Alexey V. Danilov, Habte A. Yimer, Michael A. Boxer, John M. Burke, Sunil Babu, Jia Li, Yong Mun, Peter C. Trask, Anthony S. Masaquel & Jeff P. Sharman. (2022) Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine. Clinical Lymphoma Myeloma and Leukemia 22:2, pages 121-128.
Crossref
Crossref
Mohammad Ammad Ud Din, Samarthkumar Thakkar, Harsh Patel, Hassan Saeed, Syed Ather Hussain, Hania Liaqat, Aneeqa Zafar, Sourbha S. Dani, Sarju Ganatra & Faiz Anwer. (2022) The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database. Clinical Lymphoma Myeloma and Leukemia 22:2, pages 98-104.
Crossref
Crossref
Lukáš Smolej. 2022.
Alessandra TedeschiAnna Maria FrustaciFrancesca Romana MauroAnnalisa ChiarenzaMarta CosciaStefania CiolliGianluigi RedaLuca Laurenti, Marzia VarettoniRoberta MurruClaudia BaratèPaolo SportolettiAntonino GrecoChiara BorellaValentina Rossi, Marina DeodatoAnnalisa Biagi, Giulia ZamprognaAngelo Curto PelleGianfranco LapietraCandida Vitale, Francesca MorelliRamona CassinAlberto FresaChiara CavalloniMassimiliano Postorino, Claudia IeloRoberto CairoliFrancesco Di RaimondoMarco MontilloGiovanni Del Poeta. (2021) Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?. Blood Advances 5:24, pages 5490-5500.
Crossref
Crossref
Stefano Molica, John F. Seymour & Aaron Polliack. (2021) A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents. Hematological Oncology 39:5, pages 595-604.
Crossref
Crossref
Alberto Fresa, Francesco Autore, Eugenio Galli, Annamaria Tomasso, Luca Stirparo, Idanna Innocenti & Luca Laurenti. (2021) Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review. Journal of Clinical Medicine 10:21, pages 5104.
Crossref
Crossref
Max J. Gordon, Andy Kaempf, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, Brian T. Hill, Hamood Alqahtani, Michael Choi, Michael C. Churnetski, Jonathon B. Cohen, Deborah M. Stephens, Tanya Siddiqi, Xavier Rivera, Daniel Persky, Paul Wisniewski, Krish Patel, Mazyar Shadman, Byung Park & Alexey V. Danilov. (2021) The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clinical Cancer Research 27:17, pages 4814-4824.
Crossref
Crossref
Emelie Curovic Rotbain, Carsten Utoft Niemann, Klaus Rostgaard, Caspar da Cunha-Bang, Henrik Hjalgrim & Henrik Frederiksen. (2021) Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death. Leukemia 35:9, pages 2570-2580.
Crossref
Crossref
Lukáš Smolej, Pavel Vodárek, Dominika Écsiová & Martin Šimkovič. (2021) Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. Cancers 13:13, pages 3134.
Crossref
Crossref
Hee Jeong Cho & Sang Kyun Sohn. (2021) An Updated Review of Chronic Lymphocytic Leukemia. The Korean Journal of Medicine 96:3, pages 195-208.
Crossref
Crossref
Lukáš Smolej, Yvona Brychtová, Eduard Cmunt, Michael Doubek, Martin Špaček, David Belada, Martin Šimkovič, Lukáš Stejskal, Irena Zygulová, Renata Urbanová, Martin Brejcha, Jana Zuchnická, Heidi Móciková & Tomáš Kozák. (2021) Low‐dose fludarabine and cyclophosphamide combined with rituximab in the first‐line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long‐term results of project Q‐lite by the Czech CLL Study Group. British Journal of Haematology 193:4, pages 769-778.
Crossref
Crossref
Max J. Gordon, Julie Huang, Rebecca J. Chan, Pankaj Bhargava & Alexey V. Danilov. (2020) Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. British Journal of Haematology 192:4, pages 720-728.
Crossref
Crossref
Alicia Villavicencio, Marta Solans, Lluís Zacarías-Pons, Anna Vidal, Montse Puigdemont, Josep Maria Roncero, Marc Saez & Rafael Marcos-Gragera. (2021) Comorbidities at Diagnosis, Survival, and Cause of Death in Patients with Chronic Lymphocytic Leukemia: A Population-Based Study. International Journal of Environmental Research and Public Health 18:2, pages 701.
Crossref
Crossref
Alexey V. Danilov & Veronika Bachanova. 2021. Blood and Marrow Transplant Handbook. Blood and Marrow Transplant Handbook
347
353
.
Alessandra Tedeschi. (2020) What is Fitness in the Era of Targeted Agents?. Clinical Lymphoma Myeloma and Leukemia 20, pages S84-S86.
Crossref
Crossref
Alexey V. Danilov, Charles Herbaux, Harriet S. Walter, Peter Hillmen, Simon A. Rule, Ebenezer A. Kio, Lionel Karlin, Martin J.S. Dyer, Siddhartha S. Mitra, Ping Cheng Yi, Rita Humeniuk, Xi Huang, Ziqian Zhou, Pankaj Bhargava, Juliane M. Jürgensmeier & Christopher D. Fegan. (2020) Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research 26:12, pages 2810-2818.
Crossref
Crossref
Francesco Autore, Idanna Innocenti, Francesco Corrente, Maria Ilaria Del Principe, Serena Rosati, Paolo Falcucci, Alberto Fresa, Esmeralda Conte, Maria Assunta Limongiello, Daniela Renzi, Laura De Padua, Alessandro Andriani, Francesco Pisani, Giuseppe Cimino, Agostino Tafuri, Marco Montanaro, Francesca Romana Mauro, Giovanni Del Poeta & Luca Laurenti. (2020) Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. Frontiers in Oncology 10.
Crossref
Crossref
Andrew Rogers & Jennifer A. Woyach. (2020) BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. Therapeutic Advances in Hematology 11, pages 204062072091299.
Crossref
Crossref
Candida Vitale, Lorenzo Falchi, Maria Ciccone, Jan Burger, Naveen Pemmaraju, Gautam Borthakur, William G. Wierda, Michael J. Keating & Alessandra Ferrajoli. (2020) Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. Journal of Geriatric Oncology 11:1, pages 19-23.
Crossref
Crossref
Valentin Goede, Michael Hallek & Barbara Eichhorst. 2020. Geriatric Oncology. Geriatric Oncology
521
533
.
Ronan W. Hsieh, Ronald S. Go, Jithma P. Abeykoon, Prashant Kapoor, Shaji K. Kumar, Morie A. Gertz, Francis K. Buadi, Nelson Leung, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Rahma M. Warsame, Angela Dispenzieri, Martha Q. Lacy, Robert A. Kyle, S. Vincent Rajkumar & Jonas Paludo. (2019) Characteristics of long‐term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer 125:20, pages 3574-3581.
Crossref
Crossref
Paolo Strati & Alessandra Ferrajoli. (2019) Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach. Drugs & Aging 36:9, pages 841-851.
Crossref
Crossref
Steven E. CoutreJohn C. ByrdPeter HillmenJacqueline C. BarrientosPaul M. BarrStephen DevereuxTadeusz RobakThomas J. KippsAnna SchuhCarol MorenoRichard R. FurmanJan A. Burger, Michael O’Dwyer, Paolo Ghia, Rudolph Valentino, Stephen Chang, James P. Dean, Danelle F. James & Susan M. O’Brien. (2019) Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Advances 3:12, pages 1799-1807.
Crossref
Crossref
Valentin Goede & Reinhard Stauder. (2019) Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology. Journal of Geriatric Oncology 10:3, pages 497-503.
Crossref
Crossref
Peter Georgantopoulos, Huiying Yang, LeAnn B. Norris & Charles L. Bennett. (2019) Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors. Cancer Medicine 8:5, pages 2233-2240.
Crossref
Crossref
Martin Špaček, Petra Obrtlíková, Stanislava Hrobková, Eduard Cmunt, Josef Karban, Jan Molinský, Martin Šimkovič, Heidi Mociková, Lekaa Mohammadová, Anna Panovská, Jan Novák, Marek Trněný, Lukáš Smolej & Michael Doubek. (2019) Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. Leukemia Research 79, pages 17-21.
Crossref
Crossref
Róbert Szász, Elvira Altai, Katalin Pál, Péter Dombi, János Iványi, János Jakucs, Natália Jóni, Árpád Illés, Ilona Tárkányi, László Szerafin, Zsolt Nagy, Péter Farkas, Ágnes Nagy, Klára Piukovics, György Ujj & Tamás Schneider. (2018) Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study). Pathology & Oncology Research 25:2, pages 535-540.
Crossref
Crossref
Erden ATİLLA, Fulya ÖZEL, Pınar ATACA ATİLLA, Pervin TOPÇUOĞLU, Hamdi AKAN, Meral BEKSAÇ, Osman İLHAN, Muhit ÖZCAN, Önder ARSLAN, Günhan GÜRMAN & Selami Koçak TOPRAK. (2018) KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?Is Hypogammaglobulinemia Present at Diagnosis of Chronic Lymphocytic Leukemia effective on Survival and Risks of Infection?. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 20:3, pages 294-299.
Crossref
Crossref
Barbara Eichhorst, Michael Hallek & Valentin Goede. (2018) Management of unfit elderly patients with chronic lymphocytic leukemia. European Journal of Internal Medicine 58, pages 7-13.
Crossref
Crossref
Vladimir Strugov, Elena Stadnik, Yulia Virts, Tatyana Andreeva & Andrey Zaritskey. (2018) Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia. Annals of Hematology 97:11, pages 2153-2161.
Crossref
Crossref
Susan O'Brien, Peter Hillmen, Steven Coutre, Paul M. Barr, Graeme Fraser, Alessandra Tedeschi, Jan A. Burger, Marie-Sarah Dilhuydy, Georg Hess, Carol Moreno, Paula Cramer, Emily Liu, Stephen Chang, Jessica Vermeulen, Lori Styles, Angela Howes, Danelle F. James, Kalpesh Patel, Thorsten Graef & Rudolph Valentino. (2018) Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:10, pages 648-657.e15.
Crossref
Crossref
Anna H. Schuh, Nilima Parry-Jones, Niamh Appleby, Adrian Bloor, Claire E. Dearden, Christopher Fegan, George Follows, Christopher P. Fox, Sunil Iyengar, Ben Kennedy, Helen McCarthy, Helen M. Parry, Piers Patten, Andrew R. Pettitt, Ingo Ringshausen, Renata Walewska & Peter Hillmen. (2018) Guideline for the treatment of chronic lymphocytic leukaemia. British Journal of Haematology 182:3, pages 344-359.
Crossref
Crossref
Max J. Gordon, Michael Churnetski, Hamood Alqahtani, Xavier Rivera, Adam Kittai, Stephen M. Amrock, Spencer James, Sheila Hoff, Sudhir Manda, Stephen E. Spurgeon, Michael Choi, Jonathon B. Cohen, Daniel Persky & Alexey V. Danilov. (2018) Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer 124:15, pages 3192-3200.
Crossref
Crossref
Marcel Reiser, Steffen Dörfel, Manfred Hensel, Mark Hoesl, Wolf-Oliver Jordan, Michael Koenigsmann, Dirk Meyer, Dietmar Reichert, Andreas Schwarzer, Moritz Marquardt, Kerstin Kellershohn & Kathleen Jentsch-Ullrich. (2018) Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice. European Journal of Haematology 100:5, pages 455-464.
Crossref
Crossref
Yuanjia Zhu, Andrew J. Toth, Ashley M. Lowry, Eugene H. Blackstone, Brian T. Hill & Stephanie L. Mick. (2018) Cardiac Surgery Outcomes in Patients With Chronic Lymphocytic Leukemia. The Annals of Thoracic Surgery 105:4, pages 1182-1191.
Crossref
Crossref
C. Buske, M. Hutchings, M. Ladetto, V. Goede, U. Mey, P. Soubeyran, M. Spina, R. Stauder, M. Trněný, U. Wedding, P. Fields, Christian Buske, Martin Dreyling, Andrés J M Ferreri, Paul Fields, Gianluca Gaidano, Valentin Goede, Martin Hutchings, Marco Ladetto, Steven Le Gouill, Stefano Luminari, Ulrich Mey, Peter de Nully Brown, Michael Pfreundschuh, Christiane Pott, Norbert Schmitz, Pierre Soubeyran, Michele Spina, Reinhard Stauder, Anna Sureda Balari, Marek Trněný, Gustaaf van Imhoff, Jan Walewski, Ulrich Wedding, Alberto Zamò & Emanuele Zucca. (2018) ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Annals of Oncology 29:3, pages 544-562.
Crossref
Crossref
Anthony Mato, Chadi Nabhan, Neil E. Kay, Nicole Lamanna, Thomas J. Kipps, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Shriya Bhushan, Kristen Sullivan, E. Dawn Flick & Jeff P. Sharman. (2018) Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clinical Lymphoma Myeloma and Leukemia 18:2, pages 114-124.e2.
Crossref
Crossref
Valentin Goede, Michael Hallek & Barbara Eichhorst. 2018. Geriatrische Onkologie. Geriatrische Onkologie
249
260
.
Valentin Goede, Michael Hallek & Barbara Eichhorst. 2017. Geriatric Oncology. Geriatric Oncology
1
13
.
Eric M. Ammann, Tait D. Shanafelt, Melissa C. Larson, Kara B. Wright, Bradley D. McDowell, Brian K. Link & Elizabeth A. Chrischilles. (2017) Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma and Leukemia 17:12, pages e11-e25.
Crossref
Crossref
Godelieve Meunier, Loic Ysebaert, Phi Linh Nguyen-Thi, Stéphane Lepretre, Anne Quinquenel, Jehan Dupuis, Richard Lemal, Thérèse Aurran, Cécile Tomowiak, Florence Cymbalista, Marie Sarah Dilhuydy, Annie Brion, Pierre Morel, Bruno Cazin, Véronique Leblond, Guillaume Cartron, Daniel Ré, Marie Christine Béné, Anne Sophie Michallet & Pierre Feugier. (2017) First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. Hematological Oncology 35:4, pages 671-678.
Crossref
Crossref
Paul J. Hampel, Kari G. Chaffee, Rebecca L. King, Douglas Simonetto, Melissa C. Larson, Sara Achenbach, Timothy G. Call, Wei Ding, Saad S. Kenderian, Jose F. Leis, Asher A. Chanan-Khan, Deborah A. Bowen, Michael J. Conte, Susan M. Schwager, Curtis A. Hanson, Susan L. Slager, Neil E. Kay, Tait D. Shanafelt & Sameer A. Parikh. (2017) Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. American Journal of Hematology 92:12, pages 1362-1369.
Crossref
Crossref
Alexey V. Danilov, Lionel D. Lewis, Frederick Lansigan, Liya Roudaia, Darcie L. Findley, Susan Y. Jones, Brian Highhouse, Bernard B. Beaulieu & Jennifer R. Brown. (2017) A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. British Journal of Haematology 178:5, pages 820-823.
Crossref
Crossref
Paolo Strati, Sameer A. Parikh, Kari G. Chaffee, Neil E. Kay, Timothy G. Call, Sara J. Achenbach, James R. Cerhan, Susan L. Slager & Tait D. Shanafelt. (2017) Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. British Journal of Haematology 178:3, pages 394-402.
Crossref
Crossref
Constantine Tam, Bryone Kuss, Stephen Opat, Joy Boulos & Paula Marlton. (2017) Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil. Internal Medicine Journal 47, pages 5-10.
Crossref
Crossref
Francesca R. Mauro, Fortunato Morabito, Iolanda D. Vincelli, Luigi Petrucci, Melissa Campanelli, Adriano Salaroli, Giuseppina Uccello, Annamaria Petrungaro, Francesca Ronco, Sara Raponi, Mauro Nanni, Antonino Neri, Manlio Ferrarini, Anna R. Guarini, Robin Fo?Massimo Gentile. (2017) Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. Leukemia Research 57, pages 65-71.
Crossref
Crossref
R. Stauder, B. Eichhorst, M.E. Hamaker, K. Kaplanov, V.A. Morrison, A. Österborg, I. Poddubnaya, J.A. Woyach, T. Shanafelt, L. Smolej, L. Ysebaert & V. Goede. (2017) Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Annals of Oncology 28:2, pages 218-227.
Crossref
Crossref
Lauren M. Jacobs, Peter H. Wiernik, Janice P. Dutcher & Pablo Muxi. (2017) Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab. Journal of Investigative Medicine High Impact Case Reports 5:1, pages 232470961769130.
Crossref
Crossref
Valentin Goede, Michael Hallek & Barbara Eichhorst. 2017. Geriatrische Onkologie. Geriatrische Onkologie
1
12
.
C da Cunha-Bang, J Simonsen, K Rostgaard, C Geisler, H Hjalgrim & C U Niemann. (2016) Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer Journal 6:11, pages e499-e499.
Crossref
Crossref
Caspar da Cunha-Bang, Ilse Christiansen & Carsten Utoft Niemann. (2016) The CLL-IPI applied in a population-based cohort. Blood 128:17, pages 2181-2183.
Crossref
Crossref
Jacqueline C Barrientos. (2016) Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncology 12:18, pages 2077-2094.
Crossref
Crossref
Barbara Eichhorst, Michael Hallek & Valentin Goede. (2016) New treatment approaches in CLL: Challenges and opportunities in the elderly. Journal of Geriatric Oncology 7:5, pages 375-382.
Crossref
Crossref
Nora Eisemann, Maike Schnoor & Alexander Katalinic. (2016) Prediction of chronic lymphocytic leukaemia incidence in Germany and of patients ineligible for standard chemotherapy. Hematological Oncology 34:2, pages 93-101.
Crossref
Crossref
Tom Fleischer, Tung-Ti Chang, Jen-Huai Chiang, Ching-Yun Hsieh, Mao-Feng Sun & Hung-Rong Yen. (2016) Integration of Chinese Herbal Medicine Therapy Improves Survival of Patients With Chronic Lymphocytic Leukemia. Medicine 95:21, pages e3788.
Crossref
Crossref
B M Solomon, K G Chaffee, J Moreira, S M Schwager, J R Cerhan, T G Call, N E Kay, S L Slager & T D Shanafelt. (2015) Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia 30:2, pages 331-336.
Crossref
Crossref
Sarah Wall & Jennifer A. Woyach. (2016) Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. Clinics in Geriatric Medicine 32:1, pages 175-189.
Crossref
Crossref
Joseph Maly & James S. Blachly. (2016) Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. Current Hematologic Malignancy Reports 11:1, pages 52-60.
Crossref
Crossref
V.I. Bakhtina, I.V. Demko, A.N. Narkevich & D.S. Gushchin. (2016) Factors Affecting Course and Outcome of Chronic Lymphocytic Leukemia: Data from Hematological Hospitals of Krasnoyarsk Region. Clinical oncohematology 9:4, pages 413-419.
Crossref
Crossref
Vladimir Vladimirovich Strugov, E.A. Stadnik, Yu.V. Virts, T.O. Silina & A.Yu. Zaritskii. (2016) Role of Patient's Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia. Clinical oncohematology 9:2, pages 162-175.
Crossref
Crossref
Susan M. O'BrienNicole LamannaThomas J. KippsIan FlinnAndrew D. ZelenetzJan A. BurgerMichael KeatingSiddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger D. Dansey, Ronald L. Dubowy & Steven E. Coutre. (2015) A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood 126:25, pages 2686-2694.
Crossref
Crossref
Kanti R. Rai. (2015) Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Alicia Snowden, Ingrid Hayden, Joanna Dixon & Gareth Gregory. (2015) Prevention and management of obinutuzumab-associated toxicities: Australian experience. International Journal of Nursing Practice 21, pages 15-27.
Crossref
Crossref
Helen M. Parry, Jane Birtwistle, Alison Whitelegg, Chris Hudson, Tina McSkeane, Peter Hazlewood, Nyasha Mudongo, Guy Pratt, Paul Moss, Mark T. Drayson, Jim Murray & Alex G. Richter. (2015) Poor functional antibody responses are present in nearly all patients with chronic lymphocytic leukaemia, irrespective of total IgG concentration, and are associated with increased risk of infection. British Journal of Haematology 171:5, pages 887-890.
Crossref
Crossref
Valentin Goede & Michael Hallek. (2015) Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope. Drugs & Aging 32:11, pages 877-886.
Crossref
Crossref
Luca Laurenti, Idanna Innocenti, Francesco Autore, Barbara Vannata, Dimitar G. Efremov, Stefania Ciolli, Giovanni Del Poeta, Francesca Romana Mauro, Agostino Cortelezzi, Paola Anticoli Borza, Francesco Ghio, Patrizia Mondello, Roberta Murru, Alessandro Gozzetti, Maria Rosa Lanza Cariccio, Nicola Piccirillo, Riccardo Boncompagni, Maria Cantonetti, Maria Ilaria Del Principe, Gianluigi Reda, Velia Bongarzoni, Giulia Cervetti, Vincenzo Pitini, Robin Fo?Simona Sica & Giovanni D?Arena. (2015) Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. Leukemia Research 39:10, pages 1066-1070.
Crossref
Crossref
Bradley Heraly & Vicki A. Morrison. (2015) How I treat chronic lymphocytic leukemia in older patients. Journal of Geriatric Oncology 6:5, pages 333-340.
Crossref
Crossref
Francesco Merli, Caterina Mammi & Fiorella Ilariucci. (2015) Integrating Oncogeriatric Tools into the Management of Chronic Lymphocytic Leukemia: Current State of the Art and Challenges for the Future. Current Oncology Reports 17:7.
Crossref
Crossref
Carolyn Owen, Isabelle Bence-Bruckler, Inès Chamakhi, Cynthia Toze, Wissam Assaily, Anna Christofides & Sue Robinson. (2015) A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 15:6, pages 303-313.
Crossref
Crossref
V. Goede & M. Hallek. (2015) Chronische lymphatische Leuk?mie beim alten PatientenChronic lymphocytic leukemia in elderly patients. Der Onkologe 21:6, pages 486-495.
Crossref
Crossref
Angela E. Foster, TuDung T. Nguyen, Noor Al-HammadiJohn L. Frater, Anjum Hassan & Friederike Kreisel. (2015) Clinical Presentation, Progression, and Outcome of Patients With Clonal B-Cell Counts of Less Than 5 × 109/L, 5 to 10 × 109/L, and More Than 10 × 109/L and Chronic Lymphocytic Leukemia Immunophenotype. American Journal of Clinical Pathology 143:1, pages 70-77.
Crossref
Crossref
Valentin Goede & Michael Hallek. 2015. Management of Hematological Cancer in Older People. Management of Hematological Cancer in Older People
113
128
.
Martine Extermann. 2015. Management of Hematological Cancer in Older People. Management of Hematological Cancer in Older People
219
237
.
Maria Ciccone & Alessandra Ferrajoli. (2014) Management of chronic lymphocytic leukemia in elderly patients. International Journal of Hematologic Oncology 3:6, pages 433-443.
Crossref
Crossref
Uri Rozovski, Inbal Hazan-Halevy, Michael J. Keating & Zeev Estrov. (2014) Personalized medicine in CLL: Current status and future perspectives. Cancer Letters 352:1, pages 4-14.
Crossref
Crossref
Sacha Satram-Hoang, Carolina Reyes, Khang Q. Hoang, Faiyaz Momin & Sandra Skettino. (2014) Treatment practice in the elderly patient with chronic lymphocytic leukemia—analysis of the combined SEER and Medicare database. Annals of Hematology 93:8, pages 1335-1344.
Crossref
Crossref
Tanya M. WildesValentin GoedePaul Hamlin. (2014) Personalizing Therapy for Older Adults with Lymphoid Malignancies: Options and Obstacles. American Society of Clinical Oncology Educational Book:34, pages e240-e248.
Crossref
Crossref
Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens M. Wendtner, Tatiana Chagorova, Javier de la Serna, Marie-Sarah Dilhuydy, Thomas Illmer, Stephen Opat, Carolyn J. Owen, Olga Samoylova, Karl-Anton Kreuzer, Stephan Stilgenbauer, Hartmut D?hner, Anton W. Langerak, Matthias Ritgen, Michael Kneba, Elina Asikanius, Kathryn Humphrey, Michael Wenger & Michael Hallek. (2014) Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. New England Journal of Medicine 370:12, pages 1101-1110.
Crossref
Crossref
Tait Shanafelt. (2013) Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology 2013:1, pages 158-167.
Crossref
Crossref
Alexey V. Danilov. (2013) Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future. Clinical Therapeutics 35:9, pages 1258-1270.
Crossref
Crossref
Stefano Molica. (2013) Chemotherapy-free treatment of chronic lymphocytic leukemia: where do we stand?. International Journal of Hematologic Oncology 2:3, pages 185-186.
Crossref
Crossref
Ohad Benjamini, Alessandra Ferrajoli & Michael J Keating. (2013) Approach to frontline therapy in elderly chronic lymphocytic leukemia patients. Aging Health 9:3, pages 331-347.
Crossref
Crossref
Anne-Sophie Michallet, Bruno Cazin, Emmanuel Bouvet, Lucie Oberic, Daniel Schlaifer, Laurent Mosser, Gilles Salles, Bertrand Coiffier, Guy Laurent & Loïc Ysebaert. (2013) First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis. Journal of Geriatric Oncology 4:2, pages 141-147.
Crossref
Crossref
Jennifer A. WoyachAmy S. RuppertKanti RaiThomas S. LinSusan GeyerJonathan KolitzFrederick R. AppelbaumMartin S. TallmanAndrew R. BelchVicki A. MorrisonRichard A. LarsonJohn C. Byrd. (2013) Impact of Age on Outcomes After Initial Therapy With Chemotherapy and Different Chemoimmunotherapy Regimens in Patients With Chronic Lymphocytic Leukemia: Results of Sequential Cancer and Leukemia Group B Studies. Journal of Clinical Oncology 31:4, pages 440-447.
Crossref
Crossref
Barry D. Hock, Liam J. Fernyhough, Sheryl M. Gough & Judith L. McKenzie. (2013) Clinical Significance of Plasma Levels of Soluble CD40 in Patients with Chronic Lymphocytic Leukemia. Open Journal of Blood Diseases 03:01, pages 1-5.
Crossref
Crossref
Sacha Satram-Hoang, Carolina Reyes, Khang Q. Hoang, Faiyaz Momin & Sandra Skettino. (2013) The Unmet Need in Chronic Lymphocytic Leukemia: Impact of Comorbidity Burden on Treatment Patterns and Outcomes in Elderly Patients. Journal of Cancer Therapy 04:08, pages 1321-1329.
Crossref
Crossref
J Moreira, K G Rabe, J R Cerhan, N E Kay, J W Wilson, T G Call, J F Leis, D F Jelinek, S M Schwager, D A Bowen, C A Hanson, S L Slager & T D Shanafelt. (2012) Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia 27:1, pages 136-141.
Crossref
Crossref
Stephanie A. Gregory. (2012) Managing the patient with chronic lymphocytic leukemia: initial evaluation and first-line treatment decisions. Community Oncology 9:12, pages S77-S84.
Crossref
Crossref
Wolfgang U. Knauf, Toshko Lissitchkov, Ali Aldaoud, Anna M. Liberati, Javier Loscertales, Raoul Herbrecht, Gunnar Juliusson, Gerhard Postner, Liana Gercheva, Stefan Goranov, Martin Becker, Hans‐Joerg Fricke, Francoise Huguet, Ilaria Del Giudice, Peter Klein, Karlheinz Merkle & Marco Montillo. (2012)
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase
III
trial
. British Journal of Haematology 159:1, pages 67-77.
Crossref
Crossref
Anne-Sophie Michallet, Pierre Feugier, Alain Delmer, Loic Ysebaert, Bruno Cazin, Caroline Dartigeas, Luc Fornecker, Eric Van de Neste, Florence Cymbalista, Vincent Lévy, Veronique Leblond & Xavier Troussard. (2012) Specific treatment modalities for elderly patients with chronic lymphocytic leukemia. Aging Health 8:3, pages 317-322.
Crossref
Crossref
Tait D. Shanafelt, Neil E. Kay, Kari G. Rabe, David J. Inwards, Clive S. Zent, Jose F. Leis, Susan M. Schwager, Carrie A. Thompson, Deborah A. Bowen, Thomas E. Witzig, Susan L. Slager & Timothy G. Call. (2011) Hematologist/oncologist disease‐specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer 118:7, pages 1827-1837.
Crossref
Crossref
Michael J Keating & Constantine TamMarco MontilloAlessandra TedeschiEnrica Morra. 2012. Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia. Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia
26
34
.
M. Extermann & U. Wedding. (2012) Comorbidity and geriatric assessment for older patients with hematologic malignancies: A review of the evidence. Journal of Geriatric Oncology 3:1, pages 49-57.
Crossref
Crossref
Tamar Tadmor & Aaron Polliack. (2012) Optimal management of older patients with chronic lymphocytic leukemia: Some facts and principles guiding therapeutic choices. Blood Reviews 26:1, pages 15-23.
Crossref
Crossref
Lev Shvidel, Andrei Braester, Osnat Bairey, Naomi Rahimi‐Levene, Abraham Klepfish, Yair Herishanu, Mordechai Shtalrid, Aaron Polliack & Alain Berrebi. (2011) Survival trends among 1,325 patients with chronic lymphocytic leukemia seen over the past 40 years in Israel. American Journal of Hematology 86:12, pages 985-992.
Crossref
Crossref
Osnat Bairey, Rosa Ruchlemer, Neomy Rahimi-Levene, Yair Herishanu, Andre Braester, Alain Berrebi, Aaron Polliack, Avraham Klepfish & Lev Shvidel. (2011) Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study. Annals of Hematology 90:10, pages 1123-1129.
Crossref
Crossref
Béla Telek, László Rejtő, Péter Batár, Gyula Reményi, Róbert Szász, Attila Kiss & Miklós Udvardy. (2011) Practical considerations and questions in the treatment of chronic lymphocytic leukemia. Orvosi Hetilap 152:24, pages 958-963.
Crossref
Crossref
Valentin Goede & Michael Hallek. (2011) Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia. Drugs & Aging 28:3, pages 163-176.
Crossref
Crossref
Paula Cramer & Michael Hallek. (2010) Prognostic factors in chronic lymphocytic leukemia—what do we need to know?. Nature Reviews Clinical Oncology 8:1, pages 38-47.
Crossref
Crossref
Francesca M Rossi, Maria Ilaria Del Principe, Davide Rossi, Maria Irno Consalvo, Fabrizio Luciano, Antonella Zucchetto, Pietro Bulian, Riccardo Bomben, Michele Dal Bo, Marco Fangazio, Dania Benedetti, Massimo Degan, Gianluca Gaidano, Giovanni Del Poeta & Valter Gattei. (2010) Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. Journal of Translational Medicine 8:1.
Crossref
Crossref
B. D. Hock, J. L. McKenzie, L. McArthur, S. Tansley, K. G. Taylor & L. J. Fernyhough. (2010) CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data. Internal Medicine Journal 40:12, pages 842-849.
Crossref
Crossref
Wei‐Gang Tong & Alessandra Ferrajoli. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy
327
337
.
Tait D. Shanafelt, Kari G. Rabe, Neil E. Kay, Clive S. Zent, Diane F. Jelinek, Megan S. Reinalda, Susan M. Schwager, Debbie A. Bowen, Susan L. Slager, Curtis A. Hanson & Timothy G. Call. (2010) Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer 116:20, pages 4777-4787.
Crossref
Crossref
Lukáš Smolej. (2010) How I Treat Elderly or Comorbid Patients with Chronic Lymphocytic Leukemia. Acta Medica (Hradec Kralove, Czech Republic) 53:4, pages 213-220.
Crossref
Crossref
Bindu Kanapuru & William B. Ershler. 2010. Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Brocklehurst's Textbook of Geriatric Medicine and Gerontology
775
790
.
Neil E. Kay, Wenting Wu, Brian Kabat, Betsy LaPlant, Thomas S. Lin, John C. Byrd, Diane F. Jelinek, Michael R. Grever, Clive S. Zent, Timothy G. Call & Tait D. Shanafelt. (2010) Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer, pages NA-NA.
Crossref
Crossref
Ana Pilar González Rodríguez, Esther González García, Carmen Fernández Álvarez, Ana Julia González Huerta & Segundo González Rodríguez. (2009) Estudio epidemiológico y comparación de los índices pronósticos del MD Anderson Cancer Center y el índice del Gruppo Italiano Malattie Ematologiche Maligne dell′ Adulto en pacientes con leucemia linfática crónica de células B. Medicina Clínica 133:5, pages 161-166.
Crossref
Crossref
Tait D. Shanafelt, Neil E. Kay, Greg Jenkins, Timothy G. Call, Clive S. Zent, Diane F. Jelinek, William G. Morice, Justin Boysen, Liam Zakko, Susan Schwager, Susan L. Slager & Curtis A. Hanson. (2009) B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 113:18, pages 4188-4196.
Crossref
Crossref
Tahamtan Ahmadi, Tapan Maniar, Stephen Schuster & Edward Stadtmauer. (2009) Chronic Lymphocytic Leukemia: New Concepts and Emerging Therapies. Current Treatment Options in Oncology 10:1-2, pages 16-32.
Crossref
Crossref
H.B. Muss. (2009) Cancer in the Elderly: a Societal Perspective from the United States. Clinical Oncology 21:2, pages 92-98.
Crossref
Crossref
Tait D. Shanafelt, Greg Jenkins, Timothy G. Call, Clive S. Zent, Susan Slager, Deborah A. Bowen, Susan Schwager, Curtis A. Hanson, Diane F. Jelinek & Neil E. Kay. (2009) Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 115:2, pages 363-372.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref
Crossref